Advanced search
Publication Cover
Acta Oncologica Volume 49, 2010 - Issue 1
Journal homepage
3,673
Views
23
CrossRef citations to date
0
Altmetric
REVIEW ARTICLE

A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma

Guanghui Gao Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
,
Xiaohua Liang Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaCorrespondence[email protected] [email protected]
,
Jingwei Jiang Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
,
Xinli Zhou Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
,
Ruofan Huang Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
,
Zhaohui Chu Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
&
Qiong Zhan Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
 show all
Pages 3-12 | Received 26 Mar 2009, Accepted 28 Jun 2009, Published online: 26 Jan 2010

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Min-Yue Zhang, Fei Gao, Yan-Wei Zhao, Bei-Wen Ni, Hong-Hui Huang & Jian Hou. (2022) Inferior survival and frequent hepatic dysfunction in non-Hodgkin’s lymphoma patients with HBV infection: a systematic review and meta-analysis. Hematology 27:1, pages 70-79.
Read now
Qingling Hua, Yanzhe Zhu & Hu Liu. (2015) Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin’s lymphoma (B-NHL) chemotherapy: a meta-analysis. Journal of Chemotherapy 27:6, pages 365-370.
Read now

Articles from other publishers (21)

Max S. Topp, Herbert Eradat, Axel Florschütz, Andreas Hochhaus, Tomasz Wrobel, Jan Walewski, Wanda Knopinska-Posluszny, Abraham S. Kanate, Ewa Lech-Maranda, Uta Brunnberg, Surya Chitra, Tina G. Nielsen, Gila Sellam, Mahesh Shivhare & Izidore S. Lossos. (2022) Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma. Journal of Cancer Research and Clinical Oncology 149:2, pages 811-817.
Crossref
Septiara Putri, Ery Setiawan, Siti Rizny F. Saldi, Levina Chandra Khoe, Euis Ratna Sari, Amila Megraini, Mardiati Nadjib, Sudigdo Sastroasmoro & Armansyah Armansyah. (2022) Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis. BMC Health Services Research 22:1.
Crossref
Luis Pérez Díaz, Susana Millán, Nuran Chaban, Ana del Campo & Eduardo Spitzer. (2021) Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. Future Oncology 17:19, pages 2529-2544.
Crossref
Kim, Lee, Eisenhut, Vliet, Kronbichler, Jeong, Shin & Gamerith. (2019) Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-analyses of Randomized Controlled Trials. Cancers 11:11, pages 1801.
Crossref
Lorenzo Falchi, Alessandra Ferrajoli, Ira Jacobs & Pilar Nava-Parada. (2018) An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia 18:8, pages 508-518.e14.
Crossref
G. A. Demyashkin, I. V. Kastyro, A. V. Sidorin & Ya. S. Borisov. (2018) The specific immunophenotypic features of nasopharyngeal carcinoma. Vestnik otorinolaringologii 83:5, pages 40.
Crossref
Paul M Maciocia, Patrycja A Wawrzyniecka, Brian Philip, Ida Ricciardelli, Ayse U Akarca, Shimobi C Onuoha, Mateusz Legut, David K Cole, Andrew K Sewell, Giuseppe Gritti, Joan Somja, Miguel A Piris, Karl S Peggs, David C Linch, Teresa Marafioti & Martin A Pule. (2017) Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nature Medicine 23:12, pages 1416-1423.
Crossref
Hasan BOSTANCI, Kürşat DİKMEN, Nalan AKYÜREK, Ahmet Çağrı BÜYÜKKASAP, Aydın YAVUZ, Mehmet Muhittin YALÇIN & Murat AKIN. (2017) Eleven patients with primary thyroid lymphoma: a single center experience. TURKISH JOURNAL OF MEDICAL SCIENCES 47, pages 1322-1327.
Crossref
Corinne Brillant, Nicole Skoetz, Sabine Kluge, Guido Schwarzer, Sven Trelle, Alexander Greb, Holger Schulz, Andreas Engert & Julia Bohlius. (2016) High-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient data. Cochrane Database of Systematic Reviews.
Crossref
Salem I. Noureldine, Emad Kandil & Ralph P. Tufano. 2016. Thyroid Cancer. Thyroid Cancer 403 410 .
Anne-Laure Gagez & Guillaume Cartron. (2014) Obinutuzumab. Current Opinion in Oncology 26:5, pages 484-491.
Crossref
Simone Lanini, Aoife C Molloy, Archibald G Prentice, Giuseppe Ippolito & Christopher C Kibbler. (2013) Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study. BMC Infectious Diseases 13:1.
Crossref
Luciane Pereira Lindenmeyer, Vanessa Hegele, Juliana Prohonoski Caregnato, Diego Wüst, Luiza Grazziotin & Paula Stoll. (2013) Follow-up of patients receiving rituximab for diffuse large B cell lymphoma: an overview of systematic reviews. Annals of Hematology 92:11, pages 1451-1459.
Crossref
Siun Walsh, Aoife J. Lowery, Denis Evoy, Enda W. McDermott & Ruth S. Prichard. (2013) Thyroid Lymphoma: Recent Advances in Diagnosis and Optimal Management Strategies. The Oncologist 18:9, pages 994-1003.
Crossref
Vanessa Hegele, Paula Stoll, Diego Wüst, Guilherme Ehrenbrink, Luiza Raquel Grazziotin, Juliana Prohonoski Caregnato & Luciane Pereira Lindenmeyer. (2013) Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?. International Journal of Clinical Pharmacy 35:4, pages 513-519.
Crossref
Allen M. Gown. 2013. Molecular Genetic Pathology. Molecular Genetic Pathology 181 196 .
S.A.M. van de Schans, D.E. Issa, O. Visser, P. Nooijen, P.C. Huijgens, H.E. Karim-Kos, M.L.G. Janssen-Heijnen & J.W.W. Coebergh. (2012) Diverging trends in incidence and mortality, and improved survival of non-Hodgkin's lymphoma, in the Netherlands, 1989–2007. Annals of Oncology 23:1, pages 171-182.
Crossref
Philip J. Bierman & James O. Armitage. 2012. Goldman's Cecil Medicine. Goldman's Cecil Medicine 1218 1228 .
Simone Lanini, Aoife C Molloy, Paul E Fine, Archibald G Prentice, Giuseppe Ippolito & Christopher C Kibbler. (2011) Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Medicine 9:1.
Crossref
Roberto Ria, Pellegrino Musto, Antonia Reale, Roberto Guariglia, Giuseppe Iodice, Franco Dammacco & Angelo Vacca. (2011) 90 Y-Ibritumomab Tiuxetan as Consolidation Therapy After Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma . Journal of Nuclear Medicine 52:6, pages 891-895.
Crossref
Olivera Markovic, Dragomir Marisavljevic, Vesna Cemerikic, Maja Perunicic, Sasa Savic, Branka Filipovic & Biljana Mihaljevic. (2011) Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL). European Journal of Haematology 86:3, pages 246-255.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.